A detailed history of Deka Bank Deutsche Girozentrale transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 75,000 shares of NTLA stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,000
Previous 75,000 -0.0%
Holding current value
$1.1 Million
Previous $1.76 Million 12.41%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$23.82 - $32.8 $74,532 - $102,631
-3,129 Reduced 4.0%
75,000 $1.99 Million
Q4 2023

Jan 24, 2024

BUY
$23.16 - $32.34 $579,000 - $808,500
25,000 Added 47.06%
78,129 $2.5 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $98,938 - $143,245
3,129 Added 6.26%
53,129 $1.68 Million
Q1 2023

Apr 24, 2023

BUY
$33.3 - $44.82 $333,000 - $448,200
10,000 Added 25.0%
50,000 $1.77 Million
Q3 2022

Nov 02, 2022

BUY
$53.92 - $71.7 $377,440 - $501,900
7,000 Added 21.21%
40,000 $2.18 Million
Q2 2022

Aug 03, 2022

BUY
$38.49 - $76.21 $50,037 - $99,072
1,300 Added 4.1%
33,000 $1.7 Million
Q1 2022

Apr 28, 2022

BUY
$58.27 - $118.99 $384,582 - $785,334
6,600 Added 26.29%
31,700 $2.29 Million
Q4 2021

Feb 02, 2022

BUY
$100.76 - $138.36 $60,456 - $83,016
600 Added 2.45%
25,100 $2.94 Million
Q2 2021

Aug 05, 2021

SELL
$60.88 - $161.91 $121,760 - $323,820
-2,000 Reduced 7.55%
24,500 $3.91 Million
Q1 2021

Apr 28, 2021

BUY
$46.59 - $83.68 $358,743 - $644,336
7,700 Added 40.96%
26,500 $1.95 Million
Q4 2020

Mar 12, 2021

BUY
$18.83 - $63.53 $58,372 - $196,943
3,100 Added 19.75%
18,800 $1.02 Million
Q3 2020

Oct 29, 2020

BUY
$17.47 - $24.93 $274,279 - $391,401
15,700 New
15,700 $335,000
Q3 2019

Nov 14, 2019

SELL
$13.07 - $18.51 $426,082 - $603,426
-32,600 Closed
0 $0
Q2 2019

Aug 01, 2019

BUY
$13.88 - $18.41 $174,888 - $231,966
12,600 Added 63.0%
32,600 $496,000
Q1 2019

May 10, 2019

BUY
$12.79 - $17.62 $47,323 - $65,194
3,700 Added 22.7%
20,000 $624,000
Q4 2018

Feb 12, 2019

SELL
$11.39 - $27.13 $42,143 - $100,381
-3,700 Reduced 18.5%
16,300 $200,000
Q3 2018

Nov 09, 2018

SELL
$25.78 - $32.6 $348,030 - $440,100
-13,500 Reduced 40.3%
20,000 $0
Q2 2018

Aug 14, 2018

BUY
$20.02 - $30.79 $60,060 - $92,370
3,000 Added 9.84%
33,500 $905,000
Q1 2018

May 03, 2018

BUY
$19.43 - $34.95 $503,237 - $905,205
25,900 Added 563.04%
30,500 $645,000
Q3 2017

Nov 06, 2017

BUY
$15.16 - $25.75 $69,736 - $118,450
4,600
4,600 $76,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.12B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.